V+ invests in AmVac AG
Zug (ots) - The Swiss biopharmaceuticals company AmVac AG in Zug has joined forces with the long-term strategic investor V+ GmbH & Co Fonds 2 KG. The private equity company based in Dresden has invested CHF 1,500,000 in AmVac AG since the first half of 2009. Last week V+ GmbH & Co Fonds 2 KG announced their intention of acquiring further shares in AmVac AG to the sum of CHF 3,000,000.00.
Michael Vogel, spokesman of the investment board: "We agree with boosting the holding because our confidence in AmVac AG has continued to grow. The extremely encouraging prospects described by AmVac for vaccines for the indications premature babies and prostatitis have convinced us. The experienced management team has also strengthened our trust. AmVac have informed us that marketing authorisations for the two vaccines FemiVac and ProstaVac are pending all over the world, and we are expecting a major return on investment in the coming years."
Melinda-Kinga Karpati, CEO of AmVac AG: "In V+ we have found an investment company that is going beyond their network to actively support us in operative positioning". This gives us enormous drive to push on with our projects full steam ahead." AmVac AG has also been able to convince other renowned private investors such as Dr. Mo Ibrahim.
AmVac AG is a biopharmaceutical company situated in Switzerland. The company focuses on the vaccine market with its above-average growth figures. There are two therapeutic vaccines in the pipeline which are soon to be launched in the fields of gynaecology and urology. Further innovative vaccines and technologies are at the development stage. The renowned market research company Frost & Sullivan awarded AmVac AG the coveted prize "Enabling Technology of the Year Award" in 2007.
V+ GmbH & Co Fonds 2 KG
V+ GmbH & Co Fonds 2 KG is one of the leading Venture Capital funds that invests in direct shareholdings and secondary market holdings in German-speaking countries.
ots Originaltext: AmVac AG
Head of PR/IR